Merck & Co. chief medical officer Eliav Barr talks with Scrip about the generational leadership change under way at the company, Merck's next oncology plays and its bold plan to rebuild a cardiovascular franchise.

Skyrizi is the first specific IL-23 inhibitor for the treatment of Crohn's disease in Europe, though the drug was approved with a broader label in the US.

Teva announced the appointment of former Sandoz CEO Richard Francis as its next leader as Kare Schultz steps down.

The antibody-drug conjugate was approved by the US FDA for the treatment of FRα-positive, platinum-resistant epithelial ovarian cancer.

Ionis will pay $80m up front to Metagenomi to access its next-generation gene-editing technology to jointly research new therapies for up to four genetic targets.

Christopher Viehbacher, former Sanofi CEO and current managing partner at Gurnet Capital, will be charged with returning Biogen to growth with a second big Alzheimer’s launch looming.